Table 1.

Summary of survival outcomes and prognostic factors in recently published studies

Ref.	Year	Patients (n)	5-yr survival	Px factor
Zink et al[82]	2001	110	32.6%	Number of mets, CEA, size of mets
Rena et al[79]	2002	80	41.1%	DFI, number of mets, CEA
Saito et al[41]	2002	165	39.6%	LN mets, CEA
Pfannschmidt et al[37]	2003	167	32.4%	LN mets, CEA, number of mets
Inoue et al[61]	2004	128	45.3%	Primary tumor stage, distribution of mets
Melloni et al[64]	2006	81	42.0%	Primary tumor stage, complete resection
Yedibela et al[58]	2006	153	37.0%	Number of mets, DFI, transfusion
Welter et al[66]	2007	169	39.1%	DFI, number of mets, LN mets
Lin et al[59]	2009	63	43.9%	DFI, type of resection
Onaitis et al[57]	2009	378	78.0%1	Age, sex, DFI, number of mets
Watanabe et al[91]	2009	113	67.8%	CEA, lymphatic invasion
Landes et al[101]	2010	40	43.4%	Prior history of liver mets
Riquet et al[67]	2010	127	41.0%	Complete resection
Zabaleta et al[104]	2011	84	54.0%	Prior history of liver mets, LN mets, DFI, number of mets

¹Indicates 3-year survival rate. mets: Metastasis. LN: Lymph node; DFI: Disease-free interval; CEA: Carcinoembryonic antigen.